HER2-targeted antibody-drug conjugate

0 marketed 2 in Phase 3

This page covers all HER2-targeted antibody-drug conjugate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 (human epidermal growth factor receptor 2).

Targets

HER2 (human epidermal growth factor receptor 2)

Phase 3 pipeline (2)

RC48-ADC · RemeGen Co., Ltd. · Oncology
RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor.
DS-8201a · Daiichi Sankyo Co., Ltd. · Oncology
DS-8201a is an anti-HER2 antibody-drug conjugate that delivers a cytotoxic payload directly to HER2-expressing cancer cells.